Cargando…

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Naomi F., Graf, Vanessa, Caussy, Cyrielle, Dufour, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028563/
https://www.ncbi.nlm.nih.gov/pubmed/35457120
http://dx.doi.org/10.3390/ijms23084305
_version_ 1784691650756345856
author Lange, Naomi F.
Graf, Vanessa
Caussy, Cyrielle
Dufour, Jean-François
author_facet Lange, Naomi F.
Graf, Vanessa
Caussy, Cyrielle
Dufour, Jean-François
author_sort Lange, Naomi F.
collection PubMed
description Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause a significant burden worldwide and therapeutic strategies are needed. This review provides an overview of the evidence on PPAR-targeted treatment of NAFLD and NASH in individuals with type 2 diabetes mellitus. We considered current evidence from clinical trials and observational studies as well as the impact of treatment on comorbid metabolic conditions such as obesity, dyslipidemia, and cardiovascular disease. Future areas of research, such as possible sexually dimorphic effects of PPAR-targeted therapies, are briefly reviewed.
format Online
Article
Text
id pubmed-9028563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90285632022-04-23 PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients Lange, Naomi F. Graf, Vanessa Caussy, Cyrielle Dufour, Jean-François Int J Mol Sci Review Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause a significant burden worldwide and therapeutic strategies are needed. This review provides an overview of the evidence on PPAR-targeted treatment of NAFLD and NASH in individuals with type 2 diabetes mellitus. We considered current evidence from clinical trials and observational studies as well as the impact of treatment on comorbid metabolic conditions such as obesity, dyslipidemia, and cardiovascular disease. Future areas of research, such as possible sexually dimorphic effects of PPAR-targeted therapies, are briefly reviewed. MDPI 2022-04-13 /pmc/articles/PMC9028563/ /pubmed/35457120 http://dx.doi.org/10.3390/ijms23084305 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lange, Naomi F.
Graf, Vanessa
Caussy, Cyrielle
Dufour, Jean-François
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
title PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
title_full PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
title_fullStr PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
title_full_unstemmed PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
title_short PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
title_sort ppar-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028563/
https://www.ncbi.nlm.nih.gov/pubmed/35457120
http://dx.doi.org/10.3390/ijms23084305
work_keys_str_mv AT langenaomif ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients
AT grafvanessa ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients
AT caussycyrielle ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients
AT dufourjeanfrancois ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients